---
title: "NewcelX reports successful FDA pre-IND meeting for NCEL-101 type 1 diabetes trial plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291578605.md"
description: "NewcelX reported a successful FDA Type B pre-IND meeting for its NCEL-101 type 1 diabetes trial plan. The FDA supported the company's CMC package and preclinical program, enabling progress into IND-enabling work. The development plan pairs NCEL-101 with Eledon’s tegoprubart as a calcineurin inhibitor-free immunosuppression approach."
datetime: "2026-07-02T18:32:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291578605.md)
  - [en](https://longbridge.com/en/news/291578605.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291578605.md)
generator: "portal-rs"
---

# NewcelX reports successful FDA pre-IND meeting for NCEL-101 type 1 diabetes trial plan

-   NewcelX reported a successful FDA Type B pre-IND meeting for NCEL-101 in type 1 diabetes, outlining a clear path toward starting clinical trials. \* FDA feedback supported the company’s CMC package and preclinical program, enabling progress into IND-enabling work. \* Development plan pairs NCEL-101 with Eledon’s tegoprubart as a calcineurin inhibitor-free immunosuppression approach. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NCEL.US](https://longbridge.com/en/quote/NCEL.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [NLSP.US](https://longbridge.com/en/quote/NLSP.US.md)
- [NLSPW.US](https://longbridge.com/en/quote/NLSPW.US.md)

## Related News & Research

- [ELDN: Tegoprubart shows superior efficacy and safety over tacrolimus in transplant trials](https://longbridge.com/en/news/295844935.md)
- [NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | NCEL Stock News](https://longbridge.com/en/news/287766589.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program](https://longbridge.com/en/news/296513179.md)
- [Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agent](https://longbridge.com/en/news/296102289.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**